<p>Note 1: The r<sup>2</sup> is calculated before 30 days after pamidronate treatment.</p><p>Note 2: The r<sup>2</sup> is calculated to evaluate the goodness of fit paraprotein concentrations.</p
<p>(a) The active osteoclast after multi-dose pamidronate administration. (b) The bone volume after ...
This study aims to characterize the pharmacodynamic properties of denosumab, a RANK ligand inhibitor...
Denosumab, a fully human monoclonal antibody to RANKL, decreases bone remodeling, increases bone den...
<p>(a) The calibration of the integrated model with denosumab according to the NTX levels. (b) The v...
<p>Evaluations of the calibration and validation of pharmacokinetic models of pamidronate and denosu...
<p>(a) The calibration of the pharmacokinetic model of denosumab. (b) The validation of the pharmaco...
<p>The calibrated parameter values of the pharmacokinetic models of pamidronate and denosumab.</p
<p>The calibrated parameter values of the integrated models with pamidronate and denosumab.</p
<p>The clinical datasets used for the calibration and validation of the integrated models with pamid...
<p>(a) The active osteoclasts after multi–dose administration every 30 days. (b) The MM-cell density...
<p>(a) Denosumab. (b) Pamidronate. m<sub>1</sub>: muscle; m<sub>2</sub>: blood; m<sub>3</sub>: bone....
<p>Note 1: the pamidronate regime consisting of the intravenous administration of 90 mg pamidronate ...
It is unclear whether the new anti-catabolic agent denosumab represents a viable alternative to the ...
It is unclear whether the new anti-catabolic agent denosumab represents a viable alternative to the ...
It is unclear whether the new anti-catabolic agent denosumab represents a viable alternative to the ...
<p>(a) The active osteoclast after multi-dose pamidronate administration. (b) The bone volume after ...
This study aims to characterize the pharmacodynamic properties of denosumab, a RANK ligand inhibitor...
Denosumab, a fully human monoclonal antibody to RANKL, decreases bone remodeling, increases bone den...
<p>(a) The calibration of the integrated model with denosumab according to the NTX levels. (b) The v...
<p>Evaluations of the calibration and validation of pharmacokinetic models of pamidronate and denosu...
<p>(a) The calibration of the pharmacokinetic model of denosumab. (b) The validation of the pharmaco...
<p>The calibrated parameter values of the pharmacokinetic models of pamidronate and denosumab.</p
<p>The calibrated parameter values of the integrated models with pamidronate and denosumab.</p
<p>The clinical datasets used for the calibration and validation of the integrated models with pamid...
<p>(a) The active osteoclasts after multi–dose administration every 30 days. (b) The MM-cell density...
<p>(a) Denosumab. (b) Pamidronate. m<sub>1</sub>: muscle; m<sub>2</sub>: blood; m<sub>3</sub>: bone....
<p>Note 1: the pamidronate regime consisting of the intravenous administration of 90 mg pamidronate ...
It is unclear whether the new anti-catabolic agent denosumab represents a viable alternative to the ...
It is unclear whether the new anti-catabolic agent denosumab represents a viable alternative to the ...
It is unclear whether the new anti-catabolic agent denosumab represents a viable alternative to the ...
<p>(a) The active osteoclast after multi-dose pamidronate administration. (b) The bone volume after ...
This study aims to characterize the pharmacodynamic properties of denosumab, a RANK ligand inhibitor...
Denosumab, a fully human monoclonal antibody to RANKL, decreases bone remodeling, increases bone den...
DOI
Add to ORKG